Crescendo Communications is handling IR duties for Silexion Ltd, the Israeli clinical stage oncology-focused biotech that is merging in a SPAC deal with Moringa Acquisition Corp.

The deal, which is expected to close during the third quarter, is valued at $62.5M.

Ilan Levin, CEO of Moringa, said Silexion is on the cutting edge of RNA therapeutics.

Its first-generation Loder product has demonstrated strong results in patients with pancreatic cancer. Loder achieved a median overall survival advantage of 9.3 months over the use of chemotherapy alone.

Levin believes the merger will provide "both our respective shareholders the opportunity to participate in the potential of Silexion’s powerful platform as a public company listed on Nasdaq.”

David Waldman heads New York-based Crescendo, which launched in 2006.